Technology Appraisal Guidance No. 423
Source: National Institute for Health and Care Excellence
1.1 Eribulin is recommended as an option for treating locally advanced or metastatic breast cancer in adults, only when:
- it has progressed after at least 2 chemotherapy regimens (which may include an anthracycline or a taxane, and capecitabine)
- the company provides eribulin with the discount agreed in the patient access scheme.
1.2 This guidance is not intended to affect the position of patients whose treatment with eribulin was started within the NHS before this guidance was published. Treatment of those patients may continue without change to whatever funding arrangements were in place for them before this guidance was published until they and their NHS clinician consider it appropriate to stop.
The guidance shown above constitutes Section 1 of the full document. A copy of the full document and a summary of the evidence is available on the Internet at
This guidance represents the view of the Institute which was arrived at after careful consideration of the available evidence. Health professionals are expected to fully take it into account when exercising their clinical judgement. This guidance does not, however, override the individual responsibility of health professionals to make appropriate decisions in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.
© Copyright National Institute for Health and Care Excellence. All rights reserved. This material may be freely reproduced for educational and not for profit purposes within the NHS. No reproduction by or for commercial organisations is permitted without the express written permission of the Institute.
Enquiries concerning the guidance should be addressed to: National Institute for Health and Care Excellence, MidCity Place, 71 High Holborn, London WC1V 6NA. email:
Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens
Issue Date: December 2016